Vaxcyte
PCVX· Manufacturing· Fiscal year ends in December
CEO pay in FY2024Stock +30.4% in FY2024
Grant E. Pickering is the CEO of Vaxcyte and was paid $39.6M in FY2024 (Dec).
Pay$100 in the stock at the end of FY20 → $235
Executives5
See all- 1Grant E. PickeringChief Executive OfficerFY2024
- 2Andrew Guggenhime, M.B.A.President and Chief Financial OfficerFY2024
- 3Jim WassilExecutive Vice President and Chief Operating OfficerFY2025
- 4Mikhail EydelmanSenior Vice President, General Counsel and Corporate SecretaryFY2024
- 5Harp DhaliwalChief Technical Operations OfficerNot disclosed
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allVaxcyte paid its one named executive on file $5.8M in FY2025 (Dec).
| Name | |||
|---|---|---|---|
| Jim WassilExecutive Vice President and Chief Operating Officer | |||
| Grant E. PickeringChief Executive Officer | Not disclosed | Not disclosed | |
| Andrew Guggenhime, M.B.A.President and Chief Financial Officer | Not disclosed | ||
| Mikhail EydelmanSenior Vice President, General Counsel and Corporate Secretary | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers19
See allThe comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board3
See all- Heath LukatchDirector · 7 yr on the boardIndependentCompensation—Paid as an executive
- Halley GilbertDirector · 5 yr on the boardIndependentAudit, Nominating and Corporate Governance (Chair)—Paid as an executive
- Olivier Brandicourt, M.D.Director · 0 yr on the boardIndependent—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 23, 2026 | FY2025 |
| Annual report | 10-K | Feb 24, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 28, 2025 | FY2024 |
| Annual report | 10-K | Feb 25, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 15, 2024 | FY2023 |
| Annual report | 10-K | Feb 27, 2024 | FY2023 |